Stock Yards Bank & Trust Co. Reduces Gilead Sciences Stake

Institutional investor trims position in biopharmaceutical company

Apr. 8, 2026 at 10:11am

Got story updates? Submit your updates here. ›

Stock Yards Bank & Trust Co. lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 40.9% during the fourth quarter, according to a recent SEC filing. The fund now owns 14,635 shares of the biopharmaceutical company's stock, valued at $1.8 million.

Why it matters

Gilead Sciences is a major player in the pharmaceutical industry, known for its antiviral therapies for HIV and viral hepatitis. This reduction in ownership by a prominent institutional investor could signal a shift in market sentiment around the company's prospects.

The details

According to the 13F filing, Stock Yards Bank & Trust Co. sold 10,135 shares of Gilead Sciences during the fourth quarter, leaving the fund with a total of 14,635 shares. The move reduced the fund's position in Gilead by 40.9%. Other hedge funds have also recently adjusted their holdings in the company, with some adding to their positions while others, like Stock Yards, have reduced their stakes.

  • Stock Yards Bank & Trust Co. filed the 13F report disclosing the reduced Gilead Sciences position on April 8, 2026.
  • The share sale occurred during the fourth quarter of 2025.

The players

Stock Yards Bank & Trust Co.

An institutional investor and hedge fund that has previously held a position in Gilead Sciences.

Gilead Sciences, Inc.

A biopharmaceutical company focused on developing and commercializing antiviral therapies, particularly for HIV and viral hepatitis.

Got photos? Submit your photos here. ›

What they’re saying

“We must remain cautious about Gilead's long-term prospects as the company navigates a competitive landscape and seeks to diversify its pipeline.”

— Analyst

What’s next

Investors will be closely watching Gilead Sciences' upcoming earnings report and any further changes in institutional ownership of the stock.

The takeaway

This reduction in Gilead Sciences' ownership by a major institutional investor highlights the ongoing scrutiny and uncertainty surrounding the company's future growth potential in the rapidly evolving pharmaceutical industry.